Daiki Tsuji

12PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEpidemiological modellingPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 19, 2026
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.

|Aug 28, 2026
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

|Jun 01, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

|Mar 06, 2026
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.

Hisanaga Nomura, Takaya Suzuki, Takashi Kojima

|Aug 27, 2025
Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide.

Takehiro Miyagi, Daiki Tsuji, Eiji Nakatani

|Nov 16, 2024
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).

Kenichi Suzuki, Takashi Yokokawa, Takashi Kawaguchi

Pageof 2

Frequent Collaborators

6 joint publications

Takashi Yokokawa

6 joint publications

Kunihiko Itoh

5 joint publications

Masahiro Hatori

4 joint publications

Kazuyoshi Kawakami